The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Open accessAbstract
The transferrin receptor 1 (TfR1), also known as cluster of differentiation 71 (CD71), is a type II transmembrane glycoprotein that binds transferrin (Tf) and performs a critical role in cellular iron uptake through the interaction with iron-bound Tf. Iron is required for multiple cellular processes and is essential for DNA synthesis and, thus, cellular proliferation. Due to its central role in cancer cell pathology, malignant cells often overexpress TfR1 and this increased expression can be associated with poor prognosis in different types of cancer. The elevated levels of TfR1 expression on malignant cells, together with its extracellular accessibility, ability to internalize, and central role in cancer cell pathology make this receptor an attractive target for antibody-mediated therapy. The TfR1 can be targeted by antibodies for cancer therapy in two distinct ways: (1) indirectly through the use of antibodies conjugated to anti-cancer agents that are internalized by receptor-mediated endocytosis or (2) directly through the use of antibodies that disrupt the function of the receptor and/or induce Fc effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC). Although TfR1 has been used extensively as a target for antibody-mediated cancer therapy over the years, interest continues to increase for both targeting the receptor for delivery purposes and for its use as direct anti-cancer agents. This review focuses on the developments in the use of antibodies targeting TfR1 as direct anti-tumor agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Campisi, A., Bonfanti, R., Raciti, G., Bonaventura, G., Legnani, L., Magro, G. G., Pennisi, M. A., Russo, G. L., Chiacchio, M. A., Pappalardo, F., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.01.003 · Cited by 44
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Rhodes, D. R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B. B., Barrette, T. R., Anstet, M. J., Kincead-Beal, C., Kulkarni, P., et al. (2007) · Neoplasia · doi:10.1593/neo.07112 · Cited by 2,060
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
The ins and outs of MHC class II-mediated antigen processing and presentation
Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207 · cited 1×
“In addition, as macrophages are also antigenpresenting cells (APCs), they can improve anti-tumor immunity through the possible induction of a secondary immune response against processed and presented tumor antigens (103, 104).”
BackgroundPotent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & Nakamura, Y. (2000) · Nature · doi:10.1038/35003506 · Cited by 904
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Self-citationRegulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729
The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
Richardson, D. R., & Ponka, P. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/s0304-4157(96)00014-7 · Cited by 704
Transferrin and transferrin receptors update
Kawabata, H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.037 · Cited by 692
Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin.
Trowbridge, I. S., & Omary, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.5.3039 · Cited by 680
Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., Jayawardena, S., De Smaele, E., Cong, R., Beaumont, C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.017 · Cited by 663
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 634
Self-citationThe transferrin receptor: role in health and disease
Ponka, P., & Lok, C. N. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00070-9 · Cited by 595
Structure of the human transferrin receptor-transferrin complex
Cheng, Y., Zak, O., Aisen, P., Harrison, S. C., & Walz, T. (2004) · Cell · doi:10.1016/s0092-8674(04)00130-8 · Cited by 571
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1
Li, L., Fang, C. J., Ryan, J. C., Niemi, E. C., Lebrón, J. A., Björkman, P. J., Arase, H., Torti, F. M., Torti, S. V., Nakamura, M. C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913192107 · Cited by 561
Richardson, D. R., Lane, D. J. R., Becker, E. M., Huang, M. L.-H., Whitnall, M., Rahmanto, Y. S., Sheftel, A. D., & Ponka, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912925107 · Cited by 536
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Self-citationTransferrin receptor 1 in cancer: a new sight for cancer therapy.
Shen, Y., Li, X., Dong, D., Zhang, B., Xue, Y., & Shang, P. (2018) · Europe PMC (PubMed Central) · Cited by 483
Iron addiction: a novel therapeutic target in ovarian cancer
Basuli, D., Tesfay, L., Deng, Z., Paul, B., Yamamoto, Y., Ning, G., Xian, W., McKeon, F., Lynch, M., Crum, C. P., et al. (2017) · Oncogene · doi:10.1038/onc.2017.11 · Cited by 465
2011: the immune hallmarks of cancer
Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 415
Trowbridge, I. S., & Lopez, F. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.4.1175 · Cited by 328
The transferrin receptor: the cellular iron gate
Gammella, E., Buratti, P., Cairo, G., & Recalcati, S. (2017) · Metallomics · doi:10.1039/c7mt00143f · Cited by 311
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control
Zhang, C. (2014) · Protein & Cell · doi:10.1007/s13238-014-0083-7 · Cited by 297
Iron Regulates the Intracellular Degradation of Iron Regulatory Protein 2 by the Proteasome
Guo, B., Phillips, J. D., Yu, Y., & Leibold, E. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21645 · Cited by 288
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 268
Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis
O'Donnell, K. A., Yu, D., Zeller, K. I., Kim, J.-W., Racke, F., Thomas-Tikhonenko, A., & Dang, C. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2373-2386.2006 · Cited by 253
Jackson, A. L., & Loeb, L. A. (1998) · Genetics · doi:10.1093/genetics/148.4.1483 · Cited by 253
A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders
Yiannikourides, A., & Latunde-Dada, G. (2019) · Medicines · doi:10.3390/medicines6030085 · Cited by 253
Xue, X., Ramakrishnan, S. K., Weisz, K., Triner, D., Xie, L., Attili, D., Pant, A., Győrffy, B., Zhan, M., Carter-Su, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.015 · Cited by 245
Ferritin: At the Crossroads of Iron and Oxygen Metabolism
Theil, E. C. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.5.1549s · Cited by 239
Habashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0345-x · Cited by 236 · cited 1×
“Increased expression of TfR1 correlates with advanced stage and/or poorer prognosis in a number of cancers, including solid cancers such as esophageal squamous cell carcinoma (56), breast cancer (57, 58), ovarian cancer (59), lung cancer (60), cervical cancer (61), bladder cancer (62), osteosarcoma (63), pancreatic ca…”
BackgroundHuman immunoglobulin allotypes: Possible implications for immunogenicity
Jefferis, R., & Lefranc, M.-P. (2009) · mAbs · doi:10.4161/mabs.1.4.9122 · Cited by 235
Crosstalk between Human IgG Isotypes and Murine Effector Cells
Overdijk, M. B., Verploegen, S., Ortiz Buijsse, A., Vink, T., Leusen, J. H. W., Bleeker, W. K., & Parren, P. W. H. I. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200356 · Cited by 229
Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation
Thomson, A. M., Rogers, J. T., & Leedman, P. J. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00080-1 · Cited by 221
Lansdorp, P. M., & Dragowska, W. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.6.1501 · Cited by 216
Gül, N., & van Egmond, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1330 · Cited by 210
Cellular and molecular mechanisms of inflammation‐induced angiogenesis
Szade, A., Grochot‐Przeczek, A., Florczyk, U., Jozkowicz, A., & Dulak, J. (2015) · IUBMB Life · doi:10.1002/iub.1358 · Cited by 199
Ryschich, E., Huszty, G., Knaebel, H. P., Hartel, M., Büchler, M. W., & Schmidt, J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.036 · Cited by 199
Human cell-surface glycoprotein with unusual properties
Omary, M. B., Trowbridge, I. S., & Minowada, J. (1980) · Nature · doi:10.1038/286888a0 · Cited by 198
Callens, C., Coulon, S., Naudin, J., Radford-Weiss, I., Boissel, N., Raffoux, E., Wang, P. H. M., Agarwal, S., Tamouza, H., Paubelle, E., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091488 · Cited by 197
Habeshaw, J. A., Lister, T. A., Stansfeld, A. G., & Greaves, M. F. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92191-8 · Cited by 190
HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation
Bianchi, L., Tacchini, L., & Cairo, G. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.21.4223 · Cited by 189
Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M., & Kay, N. E. (1994) · Clinical Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.365-372.1994 · Cited by 184
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 183
Self-citationCryo-EM structure of the human ferritin–transferrin receptor 1 complex
Montemiglio, L. C., Testi, C., Ceci, P., Falvo, E., Pitea, M., Savino, C., Arcovito, A., Peruzzi, G., Baiocco, P., Mancia, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09098-w · Cited by 175
The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Stewart, R. A., Hammond, S. A., Oberst, M. D., & Wilkinson, R. W. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0029-x · Cited by 171
The Regulation of Cellular Iron Metabolism
Chua, A. C. G., Graham, R. M., Trinder, D., & Olynyk, J. K. (2007) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360701428257 · Cited by 168
Evolutionary Conserved Regulation of HIF-1β by NF-κB
van Uden, P., Kenneth, N. S., Webster, R., Müller, H. A., Mudie, S., & Rocha, S. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001285 · Cited by 163
Oncogenic regulation of tumor metabolic reprogramming
Tarrado-Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 161
Eckenroth, B. E., Steere, A. N., Chasteen, N. D., Everse, S. J., & Mason, A. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105786108 · Cited by 160
Torti, S. V., & Torti, F. M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100860 · Cited by 153
Golay, J., & Introna, M. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.02.011 · Cited by 150
Boult, J. K. R., Roberts, K., Brookes, M., Hughes, S., Bury, J. P., Cross, S. S., Anderson, G. J., Spychal, R., Iqbal, T. H., & Tselepis, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1054 · Cited by 149
Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis
Laskey, J. D., Webb, I. J., Schulman, H. M., & Ponka, P. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90123-1 · Cited by 145
Complement in monoclonal antibody therapy of cancer
Rogers, L. M., Veeramani, S., & Weiner, G. J. (2014) · Immunologic Research · doi:10.1007/s12026-014-8542-z · Cited by 138
Tacchini, L., Gammella, E., De Ponti, C., Recalcati, S., & Cairo, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800365200 · Cited by 132
Emerging and Dynamic Biomedical Uses of Ferritin
Chiou, B., & Connor, J. R. (2018) · Pharmaceuticals · doi:10.3390/ph11040124 · Cited by 131
Murine cell surface transferrin receptor: Studies with an anti‐receptor monoclonal antibody
Trowbridge, I. S., Lesley, J., & Schulte, R. J. (1982) · Journal of Cellular Physiology · doi:10.1002/jcp.1041120314 · Cited by 129
Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms
Kleven, M. D., Jue, S. F., & Enns, C. A. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00006 · Cited by 127
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 121
Jeong, S. M., Hwang, S., & Seong, R. H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.023 · Cited by 120
Moura, I. C. (2004) · Blood · doi:10.1182/blood-2003-07-2440 · Cited by 114
White, S., Taetle, R., Seligman, P. A., Rutherford, M., & Trowbridge, I. S. (1990) · PubMed · Cited by 112
Development of an in vivo model of human multiple myeloma bone disease
Alsina, M., Boyce, B. F., Devlin, R. D., Anderson, J. L., Craig, F. E., Mundy, G. R., & Roodman, G. D. (1996) · Blood · doi:10.1182/blood.v87.4.1495.bloodjournal8741495 · Cited by 97
Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation
Gu, Z., Wang, H., Xia, J.-L., Yang, Y., Jin, Z., Xu, H.-W., Shi, J.-M., Domenico, I. D., Tricot, G., & Zhan, F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3804 · Cited by 97
SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1
Jeong, S. M., Lee, J. J., Finley, L. W. S., Schmidt, P. J., Fleming, M. D., & Haigis, M. C. (2014) · Oncogene · doi:10.1038/onc.2014.124 · Cited by 96
Inhibition of Cell Growth by Monoclonal Anti-Transferrin Receptor Antibodies
Lesley, J., & Schulte, R. J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.8.1814 · Cited by 95
Heme Oxygenase-1: A Critical Link between Iron Metabolism, Erythropoiesis, and Development
Fraser, S. T., Midwinter, R. G., Berger, B. S., & Stocker, R. (2011) · Advances in Hematology · doi:10.1155/2011/473709 · Cited by 92
Zwaans, B. M. M., & Lombard, D. B. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.016287 · Cited by 92
Rosager, A. M., Sørensen, M. D., Dahlrot, R. H., Hansen, S., Schonberg, D. L., Rich, J. N., Lathia, J. D., & Kristensen, B. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182954 · Cited by 90
Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22323 · Cited by 87 · cited 1×
“Increased expression of TfR1 correlates with advanced stage and/or poorer prognosis in a number of cancers, including solid cancers such as esophageal squamous cell carcinoma (56), breast cancer (57, 58), ovarian cancer (59), lung cancer (60), cervical cancer (61), bladder cancer (62), osteosarcoma (63), pancreatic ca…”
BackgroundWang, M., Han, X., Zhang, L., Yang, J., Qian, J. F., Shi, Y., Kwak, L. W., Romaguera, J. E., & Yi, Q. (2007) · Leukemia · doi:10.1038/sj.leu.2404959 · Cited by 87
Yang, D. C., Wang, F., Elliott, R. L., & Head, J. F. (2001) · PubMed · Cited by 87
CHAN, K. T., Choi, M. Y., Lai, K., Tan, W., Tung, L. N., Lam, H. Y., Tong, D. K. H., Lee, N. P. Y., & Law, S. Y.-K. (2014) · Oncology Reports · doi:10.3892/or.2014.2981 · Cited by 86
Prior, R., Reifenberger, G., & Wechsler, W. (1990) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01600299 · Cited by 86
Iron metabolism gene expression and prognostic features of hepatocellular carcinoma
Shen, Y., Li, X., Zhao, B., Xue, Y., Wang, S., Chen, X., Yang, J., Lv, H., & Shang, P. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27184 · Cited by 85
Adachi, M., Kai, K., Yamaji, K., Ide, T., Noshirο, H., Kawaguchi, A., & Aishima, S. (2019) · Histopathology · doi:10.1111/his.13847 · Cited by 85
Ng, P. P., Cruz, J. S. D., Sorour, D. N., Stinebaugh, J. M., Shin, S.-U., Shin, D. S., Morrison, S. L., & Penichet, M. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362999 · Cited by 84
Self-citationKondo, K., Noguchi, M., Mukai, K., Matsuno, Y., Sato, Y., Shimosato, Y., & Monden, Y. (1990) · CHEST Journal · doi:10.1378/chest.97.6.1367 · Cited by 83
Antibody Isotypes for Tumor Immunotherapy
Kretschmer, A., Schwanbeck, R., Valerius, T., & Rösner, T. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479240 · Cited by 82
Cheng, X., Fan, K., Wang, L., Ying, X., Sanders, A. J., Guo, T., Xing, X., Zhou, M., Du, H., Hu, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2272-z · Cited by 82
Effects of anti‐transferrin receptor antibodies on growth of normal and malignant myeloid cells
Taetle, R., Honeysett, J. M., & Trowbridge, I. S. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910320314 · Cited by 81
Sun, T., Patil, R., Galstyan, A., Klymyshyn, D., Ding, H., Chesnokova, A., Cavenee, W. K., Furnari, F. B., Ljubimov, V. A., Shatalova, E. S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2725 · Cited by 79
Self-citationJian, J., Yang, Q., & Huang, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271585 · Cited by 78
Lesley, J., Schulte, R. J., & Woods, J. W. (1989) · Experimental Cell Research · doi:10.1016/0014-4827(89)90293-0 · Cited by 77
Jones, D. T., Trowbridge, I. S., & Harris, A. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3857 · Cited by 75 · cited 2×
“15 inhibits cellular proliferation in vitro (133).”
BackgroundMouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó, K., Silva, S., Pálóczi, K., Domján, G., & Falus, A. (2001) · PubMed · Cited by 75
Helguera, G. F., Jemielity, S., Abraham, J., Cordo, S. M., Martínez, M. G., Rodríguez, J. A., Bregni, C., Wang, J. J., Farzan, M., Penichet, M. L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06397-11 · Cited by 73
Self-citationMechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.
Taetle, R., Castagnola, J., & Mendelsohn, J. M. (1986) · PubMed · Cited by 72
Transferrin Receptors in Erythropoiesis
Richard, C., & Verdier, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249713 · Cited by 69
Callens, C., Moura, I. C., Lepelletier, Y., Coulon, S., Renand, A., Dussiot, M., Ghez, D., Benhamou, M., Monteiro, R. C., Bazarbachi, A. A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404958 · Cited by 67
MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1
Fu, Y., Lin, L., & Xia, L. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0155-z · Cited by 66
Essaghir, A., & Demoulin, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039666 · Cited by 65
Pegram, M. D., & Ngo, D. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.003 · Cited by 65
miR-148a regulates expression of the transferrin receptor 1 in hepatocellular carcinoma
Babu, K. R., & Muckenthaler, M. U. (2019) · Scientific Reports · doi:10.1038/s41598-018-35947-7 · Cited by 63
Brüggemann, M., Teale, C., Clark, M., Bindon, C. I., & Waldmann, H. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.9.3145 · Cited by 61
Antibody-mediated targeting of the transferrin receptor in cancer cells
Luría-Pérez, R., Helguera, G. F., & Rodríguez, J. A. (2016) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.11.004 · Cited by 61
TfR1 interacts with the IKK complex and is involved in IKK–NF-κB signalling
Kenneth, N. S., Mudie, S., Naron, S., & Rocha, S. (2012) · Biochemical Journal · doi:10.1042/bj20120625 · Cited by 60
Ng, P. P., Helguera, G. F., Daniels‐Wells, T. R., Lomas, S. Z., Rodríguez, J. A., Schiller, G. J., Bonavida, B., Morrison, S. L., & Penichet, M. L. (2006) · Blood · doi:10.1182/blood-2006-04-020263 · Cited by 59
Self-citationCrépin, R., Goenaga, A.-L., Jullienne, B., Bougherara, H., Legay, C., Benihoud, K., Marks, J. D., & Poul, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0938 · Cited by 59
Xiao, C., Fu, X., Wang, Y., Liu, H., Jiang, Y., Zhao, Z., & You, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243812 · Cited by 56
Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Brooks, D., Taylor, C. G., Santos, B. D., Linden, H. C. D. V., Houghton, A., Hecht, T. T., Kornfeld, S. A., & Taetle, R. (1995) · PubMed · Cited by 55
Transferrin receptor-involved HIF-1 signaling pathway in cervical cancer
Xu, X., Liu, T., Wu, J., Wang, Y., Hong, Y., & Zhou, H. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0078-x · Cited by 54
A versatile targeting system with lentiviral vectors bearing the biotin‐adaptor peptide
Morizono, K., Xie, Y., Helguera, G. F., Daniels‐Wells, T. R., Lane, T. F., Penichet, M. L., & Chen, I. S. Y. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1345 · Cited by 53
Self-citationBiological determinants of health disparities in multiple myeloma
Smith, C. J., Ambs, S., & Landgren, O. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0118-z · Cited by 51
Sauvage, C. A., Mendelsohn, J., Lesley, J., & Trowbridge, I. S. (1987) · PubMed · Cited by 49
Dai, J., Jian, J., Bosland, M. C., Frenkel, K., Bernhardt, G., & Huang, X. (2007) · The Breast · doi:10.1016/j.breast.2007.08.009 · Cited by 48
Jamnongkan, W., Thanan, R., Techasen, A., Namwat, N., Loilome, W., Intarawichian, P., Titapun, A., & Yongvanit, P. (2017) · Tumor Biology · doi:10.1177/1010428317717655 · Cited by 48
Lepelletier, Y., Camara‐Clayette, V., Jin, H., Hermant, A., Coulon, S., Dussiot, M., Arcos‐Fajardo, M., Baude, C., Canionni, D., Delarue, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1962 · Cited by 47
Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma
Wu, H., Zhang, J., Dai, R., Xu, J., & Feng, H. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1301-z · Cited by 47
Sakamoto, S., Kawabata, H., Masuda, T., Uchiyama, T., Mizumoto, C., Ohmori, K., Koeffler, H. P., Kadowaki, N., & Takaori‐Kondo, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139915 · Cited by 46
Parenti, R., Salvatorelli, L., & Magro, G. G. (2014) · International Journal of Endocrinology · doi:10.1155/2014/685396 · Cited by 44
Jiang, X., & Elliott, R. L. (2017) · Anticancer Research · doi:10.21873/anticanres.11567 · Cited by 44
Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer
Wilke, C. M., Kryczek, I., & Zou, W. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.567362 · Cited by 43
Daniels‐Wells, T. R., Ng, P. P., Delgado, T., Lynch, M., Schiller, G. J., Helguera, G. F., & Penichet, M. L. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0330 · Cited by 42
Self-citationBiochemical modification of streptavidin and avidin: in vitro and in vivo analysis.
Rosebrough, S. F., & Hartley, D. F. (1996) · PubMed · Cited by 42
Shimosaki, S., Nakahata, S., Ichikawa, T., Kitanaka, A., Kameda, T., Hidaka, T., Kubuki, Y., Kurosawa, G., Zhang, L., Sudo, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.039 · Cited by 41
Ortíz-Sánchez, E., Daniels‐Wells, T. R., Helguera, G. F., Martínez-Maza, O., Bonavida, B., & Penichet, M. L. (2008) · Leukemia · doi:10.1038/leu.2008.270 · Cited by 40
Self-citationMason, A. B., Byrne, S. L., Everse, S. J., Roberts, S. E., Chasteen, N. D., Smith, V. C., MacGillivray, R. T. A., Kandemir, B., & Bou‐Abdallah, F. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.979 · Cited by 40
Gupta, A. D., & Vi, S. (1990) · PubMed · Cited by 40
Smith, N., Strutton, G., Walsh, M. D., WRIGHT, G. R., Seymour, G. J., Lavin, M. F., & Gardiner, R. A. (1990) · British Journal of Urology · doi:10.1111/j.1464-410x.1990.tb14752.x · Cited by 39
Gross, S. A., Helm, K. M., Gruntmeir, J. J., Stillman, W. S., Pyatt, D. W., & Irons, R. D. (1997) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1997.tb01693.x · Cited by 37
Rodríguez, J. A., Helguera, G. F., Daniels‐Wells, T. R., Neacato, I. I., López-Valdés, H. E., Charles, A. C., & Penichet, M. L. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.020 · Cited by 36
Self-citationDaniels‐Wells, T. R., Ortíz-Sánchez, E., Luría-Pérez, R., Quintero, R., Helguera, G. F., Bonavida, B., Martínez-Maza, O., & Penichet, M. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318222ffc8 · Cited by 36
Self-citationKemp, J. D., Thorson, J., McAlmont, T. H., Horowitz, M. C., Cowdery, J. S., & Ballas, Z. K. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.8.2422 · Cited by 35
VanderWall, K., Daniels‐Wells, T. R., Penichet, M. L., & Lichtenstein, A. K. (2013) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2013007934 · Cited by 34
Self-citationQing, Y., Wang, S., Zhihua, W., Huifen, Z., Lei, P., Lijiang, L., Xiao-rong, Z., Liming, C., Daiwen, X., Huang, Y., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0105-7 · Cited by 34
Daniels‐Wells, T. R., Neacato, I. I., Rodríguez, J. A., Pandha, H., Morgan, R., & Penichet, M. L. (2010) · Leukemia · doi:10.1038/leu.2010.142 · Cited by 33
Self-citationHong, Y., Yang, J., Shen, X., Zhu, H., Sun, X., Wen, X., Bian, J., Hu, H., Yuan, L., Tao, J., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1337-y · Cited by 33
Daniels‐Wells, T. R., Helguera, G. F., Rodríguez, J. A., Leoh, L. S., Erb, M. A., Diamante, G., Casero, D., Pellegrini, M. A., Martínez-Maza, O., & Penichet, M. L. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.10.006 · Cited by 33
Self-citationSakurai, K., Sohda, T., Ueda, S., Tanaka, T., Hirano, G., Yokoyama, K., Morihara, D., 阿南, 章., Takeyama, Y., Irie, M., et al. (2014) · PubMed · Cited by 33
Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors
Pizzamiglio, S., Bortoli, M. D., Taverna, E., Signore, M., Veneroni, S., Cho, W., Orlandi, R., Verderio, P., & Bongarzone, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020410 · Cited by 33
Leoh, L. S., Kim, Y. K., Candelaria, P. V., Martínez-Maza, O., Daniels‐Wells, T. R., & Penichet, M. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700787 · Cited by 33
Self-citationNeiveyans, M., Melhem, R., Arnoult, C., Bourquard, T., Jarlier, M., Busson, M., Laroche, A., Cérutti, M., Pugnière, M., Ternant, D., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1564510 · Cited by 32
Nagai, K., Nakahata, S., Shimosaki, S., Tamura, T., Kondo, Y., Baba, T., Taki, T., Taniwaki, M., Kurosawa, G., Sudo, Y., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.267 · Cited by 29
Taetle, R., & Honeysett, J. M. (1987) · PubMed · Cited by 28
Downregulation of transferrin receptor surface expression by intracellular antibody
Peng, J., Wu, S., Zhao, X., Wang, M., Li, W.-H., Shen, X., Liu, J., Lei, P., Zhu, H., & Shen, G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.052 · Cited by 27
Bjorn, M. J., & Groetsema, G. (1987) · PubMed · Cited by 26
Lesley, J., & Schulte, R. J. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1675 · Cited by 25
Prognostic Value of Transferrin Receptor-1 (CD71) Expression in Acute Lymphoblastic Leukemia
Hagag, A. A. E., Badraia, I. M., Abdelmageed, M. M., Hablas, N. M., Hazzaa, S. M., & Nosair, N. A. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180605094706 · Cited by 25
Transferrin receptor 1 targeted optical imaging for identifying glioma margin in mouse models
Ni, X., Zhao, Y., Cai, H., Yü, Z., Wang, J., Chen, F., Yu, Y., Feng, G., & Chen, Z. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03527-3 · Cited by 25
Rodríguez, J. A., Lurı́a-Pérez, R., López-Valdés, H. E., Casero, D., Daniels‐Wells, T. R., Patel, S., Avila, D., Leuchter, R. K., So, S., Ortíz-Sánchez, E., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.596964 · Cited by 22
Self-citationYe, J., Ma, J., Liu, C., Huang, J.-X., Wang, L., & Zhong, X. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.05.013 · Cited by 22
Leoh, L. S., Daniels‐Wells, T. R., Martínez-Maza, O., & Penichet, M. L. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.07.001 · Cited by 18
Self-citationBonavida (2010) · International Journal of Oncology · doi:10.3892/ijo_00000615 · Cited by 18
Johnson, M. L., El-Khoueiry, A. B., Hafez, N., Lakhani, N. J., Mamdani, H. M., Rodon, J. A., Sanborn, R. E., Ho, T., Li, R., Waldes, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3502 · Cited by 18
Daniels‐Wells, T. R., Candelaria, P. V., Leoh, L. S., Nava, M., Martı́nez-Maza, O., & Penichet, M. L. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000304 · Cited by 17
Self-citationShen, X., Zhu, H., He, F., Xing, W., Li, L., Liu, J., Yang, J., Pan, X., Lei, P., Wang, Z., et al. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.08.022 · Cited by 16
Xu, G., Wen, X., Hong, Y., Du, H., Zhang, X., Song, J., Yin, Y., Huang, H., & Shen, G. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.07.014 · Cited by 16
Moon, S. J., Kim, J. H., Kong, S. H., & Shin, C. S. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.132 · Cited by 16
Ohno, Y., Yagi, H., Nakamura, M., Masuko, K., Hashimoto, Y., & Masuko, T. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.030 · Cited by 15
Gupta, A. D., Patil, J., & Vi, S. (1996) · PubMed · Cited by 14
Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Bahrami, S., Kazemi, B., Zali, H., Black, P. C., Basiri, A., Bandehpour, M., Hedayati, M., & Sahebkar, A. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666191016124935 · Cited by 14
Fc Receptor-Dependent Immunity
Igietseme, J. U., Zhu, X., & Black, C. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394802-1.00015-7 · Cited by 12
Ohno, Y., Yagi, H., Nakamura, M., Masuko, K., Hashimoto, Y., & Masuko, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00753.x · Cited by 10
Targeting the Transferrin Receptor to Overcome Resistance to Anti-Cancer Agents
Daniels‐Wells, T. R., Neacato, I. I., Helguera, G. F., & Penichet, M. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-474-2_2 · Cited by 2
Self-citation
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Zhou, M., Zhang, Y., Shi, L., Li, L., Zhang, D., Gong, Z., & Wu, Q. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107282 · Cited by 253
Metadata
- Authors
- Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-17
- Volume
- 12
- Pages
- 607692-607692
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3138831421
- Cited by
- 268
- References
- 166
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.